ROR1 and B-cell chronic lymphocytic leukemia: Furthermore, the anti-ROR1 blocking antibody cirmtuzumab has shown efficacy in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) trials [247].